Literature DB >> 28321535

Treatment outcome of advance staged oral cavity cancer: concurrent chemoradiotherapy compared with primary surgery.

Manupol Tangthongkum1, Virat Kirtsreesakul2, Pasawat Supanimitjaroenporn2, Peesit Leelasawatsuk2.   

Abstract

Concurrent chemoradiotherapy (CCRT) has been reported as effective and has become an acceptable treatment in advanced oral cancer. However, to date there is insufficient data to conclude that CCRT provides a good survival outcome. The purpose of this study was to compare survival rates and complications in patients with resectable advanced oral cavity squamous cell carcinoma treated with either CCRT or surgery with adjuvant radiotherapy (RT)/chemoradiotherapy (CRT). Stage III or IVa oral cavity carcinoma patients treated with curative intent by either CCRT or surgery with adjuvant RT were identified over a 7-year period (2009-2015). Survival rates and treatment complications were analyzed and compared between the two groups. 61 patients underwent CCRT and 128 patients underwent surgical excision and received postoperative RT. There was no statistically significant difference in survival outcome between the two treatment groups. 5-year overall survival rates (OS) were 33 versus 24% (P = 0.191) and the disease-specific survival rates (DSS) were 27 versus 25% (P = 0.857) when comparing the CCRT group and surgery with adjuvant RT/CRT group, respectively. Long-term complications were comparable between the two groups. CCRT has comparable survival outcome and complications for the treatment of advanced oral cavity squamous cell carcinoma, compared to surgery with adjuvant RT/CRT.

Entities:  

Keywords:  Adjuvant radiotherapy; Complications; Concurrent chemoradiotherapy; Oral cancer; Surgery; Survival rate

Mesh:

Year:  2017        PMID: 28321535     DOI: 10.1007/s00405-017-4540-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  19 in total

1.  Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.

Authors:  Aaron W Pederson; Joseph K Salama; Mary Ellen Witt; Kerstin M Stenson; Elizabeth A Blair; Everett E Vokes; Daniel J Haraf
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

2.  Swallowing after major surgery of the oral cavity or oropharynx: a prospective and longitudinal assessment of patients treated by microvascular soft tissue reconstruction.

Authors:  Pepijn A Borggreven; Irma Verdonck-de Leeuw; Rico N Rinkel; Johannes A Langendijk; Jan C Roos; Eric F L David; Remco de Bree; C René Leemans
Journal:  Head Neck       Date:  2007-07       Impact factor: 3.147

Review 3.  Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies.

Authors:  Douglas E Peterson; Wolfgang Doerr; Allan Hovan; Andres Pinto; Debbie Saunders; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-06-06       Impact factor: 3.603

4.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Authors:  Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

5.  Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients.

Authors:  Ik Jae Lee; Woong Sub Koom; Chang Geol Lee; Yong Bae Kim; Sei Whan Yoo; Ki Chang Keum; Gwi Eon Kim; Eun Chang Choi; In Ho Cha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-26       Impact factor: 7.038

6.  Chemoradiation for patients with advanced oral cavity cancer.

Authors:  Kerstin M Stenson; Rangesh Kunnavakkam; Ezra E W Cohen; Louis D Portugal; Elizabeth Blair; Daniel J Haraf; Joseph Salama; Everett E Vokes
Journal:  Laryngoscope       Date:  2010-01       Impact factor: 3.325

7.  Cancer incidence in Songkhla, southern Thailand, 1990-1994.

Authors:  P Thongsuksai; H Sriplung; T Phungrassami; P Prechavittayakul
Journal:  Southeast Asian J Trop Med Public Health       Date:  1997       Impact factor: 0.267

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx.

Authors:  Rohan R Walvekar; Ryan J Li; William E Gooding; Michael K Gibson; Dwight Heron; Jonas T Johnson; Robert L Ferris
Journal:  Laryngoscope       Date:  2008-12       Impact factor: 3.325

Review 10.  Preoperative chemoradiotherapy in the management of oral cancer: a review.

Authors:  Clemens Klug; Dominik Berzaczy; Martin Voracek; Werner Millesi
Journal:  J Craniomaxillofac Surg       Date:  2008-01-28       Impact factor: 2.078

View more
  8 in total

1.  NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.

Authors:  Cheng-Ming Hsu; Pai-Mei Lin; Hsin-Ching Lin; Yao-Te Tsai; Ming-Shao Tsai; Shau-Hsuan Li; Ching-Yuan Wu; Yao-Hsu Yang; Sheng-Fung Lin; Ming-Yu Yang
Journal:  Int J Mol Sci       Date:  2018-11-10       Impact factor: 5.923

2.  Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial.

Authors:  Asma Hayat Khan; Jawad Safdar; Saad Uddin Siddiqui
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

3.  PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.

Authors:  Shin Pai; Vijesh Kumar Yadav; Kuang-Tai Kuo; Narpati Wesa Pikatan; Chun-Shu Lin; Ming-Hsien Chien; Wei-Hwa Lee; Michael Hsiao; Shao-Chih Chiu; Chi-Tai Yeh; Jo-Ting Tsai
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 4.  Adding Concomitant Chemotherapy to Postoperative Radiotherapy in Oral Cavity Carcinoma with Minor Risk Factors: Systematic Review of the Literature and Meta-Analysis.

Authors:  Alessia Di Rito; Francesco Fiorica; Roberta Carbonara; Francesca Di Pressa; Federica Bertolini; Francesco Mannavola; Frank Lohr; Angela Sardaro; Elisa D'Angelo
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

5.  Locally Advanced Oral Cavity Cancers: What Is The Optimal Care?

Authors:  Rajab Alzahrani; Arwa Obaid; Hadi Al-Hakami; Ahmed Alshehri; Hossam Al-Assaf; Reem Adas; Eman Alduhaibi; Nabil Alsafadi; Suliman Alghamdi; Majed Alghamdi
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

6.  The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.

Authors:  Lin-Hong Wang; Mei Xu; Luo-Qin Fu; Xiao-Yi Chen; Fan Yang
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

7.  CD47-SIRPα Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma.

Authors:  Shin Pai; Oluwaseun Adebayo Bamodu; Yen-Kuang Lin; Chun-Shu Lin; Pei-Yi Chu; Ming-Hsien Chien; Liang-Shun Wang; Michael Hsiao; Chi-Tai Yeh; Jo-Ting Tsai
Journal:  Cells       Date:  2019-12-17       Impact factor: 6.600

8.  Targeting FAT1 Inhibits Carcinogenesis, Induces Oxidative Stress and Enhances Cisplatin Sensitivity through Deregulation of LRP5/WNT2/GSS Signaling Axis in Oral Squamous Cell Carcinoma.

Authors:  Tung-Nien Hsu; Chih-Ming Huang; Chin-Sheng Huang; Mao-Suan Huang; Chi-Tai Yeh; Tsu-Yi Chao; Oluwaseun Adebayo Bamodu
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.